Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Key facts

Sponsor

Beijing Biotech

Intervention

Dual-target CAR-NK cells(biological)

Enrollment

60 target

Eligibility

18-75 years · All sexes

Timeline

2026 – 2028

Study locations (1)

• Peking University Shenzhen Hospital, Shenzhen, Guangdong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07162038
  Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
  National Cancer Institute (NCI)
• RECRUITINGNANCT06790225
  Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)
  Esbjerg Hospital - University Hospital of Southern Denmark
• RECRUITINGPHASE2NCT05909059
  CAR T-cell Therapy in Patients With Renal Dysfunction
  Northside Hospital, Inc.
• RECRUITINGPHASE2NCT06042569
  Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
  City of Hope Medical Center
• RECRUITINGPHASE1, PHASE2NCT06594640
  R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1NCT05748197
  A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE3NCT05883852
  EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
  Fudan University
• ACTIVE NOT RECRUITINGPHASE1NCT05627323
  CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
  Chimeric Therapeutics

See all trials for Cerebrotendinous xanthomatosis →